Genes 101: Are Human Genes Patentable Subject Matter? by Bowman, Andrew
Richmond Journal of Law and Technology
Volume 18 | Issue 4 Article 5
2012
Genes 101: Are Human Genes Patentable Subject
Matter?
Andrew Bowman
University of Richmond
Follow this and additional works at: http://scholarship.richmond.edu/jolt
Part of the Health Law and Policy Commons, and the Intellectual Property Law Commons
This Article is brought to you for free and open access by UR Scholarship Repository. It has been accepted for inclusion in Richmond Journal of Law
and Technology by an authorized administrator of UR Scholarship Repository. For more information, please contact
scholarshiprepository@richmond.edu.
Recommended Citation
Andrew Bowman, Genes 101: Are Human Genes Patentable Subject Matter?, 18 Rich. J.L. & Tech 15 (2012).
Available at: http://scholarship.richmond.edu/jolt/vol18/iss4/5
Richmond Journal of Law & Technology                           Volume XVIII, Issue 4 
 
 
 
1 
GENES 101: ARE HUMAN GENES PATENTABLE SUBJECT 
MATTER? 
 
 
by Andrew Bowman* 
 
 
Cite as: Andrew Bowman, Genes 101: Are Human Genes Patentable Subject 
Matter?, XVIII RICH. J. L. & TECH. 15, 
http://jolt.richmond.edu/v18i4/article15.pdf. 
 
 
I. INTRODUCTION 
 
[1] Genes are the fundamental building blocks of all living things.  
They dictate hair color, eye color, even susceptibility to cancer.1  As such, 
genes inherently possess untold power.  The ability of a sole company to 
                                                          
* J.D. Candidate 2013, University of Richmond School of Law.  I would like to thank 
Professor Kristen Osenga for her helpful comments and insight in publishing this 
comment. 
 
1 See Patrick Sulem et al., Genetic determinants of hair, eye and skin pigmentation in 
Europeans, 39 NATURE GENETICS 1443, 1444, 1446, 1448 (2007); Richard Wooster et 
al., Localization of a Breast Cancer Susceptibility Gene, BRCA2, to Chromosome 13q12-
13, 265 SCI. 2088, 2089 (1994). 
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wield this omnipotence makes a human gene patent highly sought after.2  
Notwithstanding the other requirements for patentability, the eligibility of 
human genes as ‘inventions’ worthy of patent protection under 35 U.S.C. 
§ 101 has recently been called into question.  In Association for Molecular 
Pathology v. U.S. Patent and Trademark Office (“the Myriad decision”), 
the Federal Circuit answered in the affirmative.3  In arriving at this 
conclusion, the majority rejected the biological significance of the 
information contained in the deoxyribonucleic acid (“DNA”) molecule in 
favor of a purely structural approach.4  The court incorrectly concluded 
that an isolated DNA molecule is “markedly different” from native DNA 
because of minor structural differences.5  The court discounted the fact 
that both the isolated DNA and the relevant portion of the native DNA 
contain the same sequence of nucleotides and therefore the same 
biological information.6  While the Federal Circuit incorrectly considered 
this issue by narrowly looking at DNA structure, there is an alternative 
comprehensive approach that considers both important properties of DNA.  
This comment proposes a totality-of-the-circumstances approach to 
analyzing biological molecules under § 101 such that both the structure 
                                                          
2 Gene patents have broad implications in both the scientific and medical communities; 
they permit the monopolization of scientific research and genetic testing on that specific 
gene.  See generally SECRETARY’S ADVISORY COMM. ON GENETICS, HEALTH, AND 
SOC’Y, DEP’T OF HEALTH & HUMAN SERVS., GENE PATENTS AND LICENSING PRACTICES 
AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 28-31 (2010), available at 
http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_patents_report_2010.pdf; Mildred 
K. Cho et al., Effects of Patents and Licenses on the Provision of Clinical Genetic Testing 
Services, 5 J. MOLECULAR DIAGNOSTICS 3, 5-7 (2003). 
 
3 (Myriad II) 653 F.3d 1329, 1334 (Fed. Cir. 2011). 
 
4 Id. at 1352-53. 
 
5 See id. at 1353. 
 
6 See id. 
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and its information is examined.  Part II of this note reviews relevant 
precedent in patent law.  Part III analyzes the Federal Circuit’s Myriad 
decision, and Part IV explains the potential effects of the recent Supreme 
Court decision Mayo Collaborative Services v. Prometheus Laboratories.  
Finally, in Part V, the patent eligibility of human genes is examined.  
Analyzing this issue under the proposed totality-of-the-circumstances 
approach, this article concludes that isolated human genes are not 
patentable. 
 
II. GENE PATENT PRECEDENT 
 
[2] In order to obtain a patent, an invention must comply with Title 35 
requirements for patentability.7  Subject matter eligible for patent 
protection is defined in § 101the invention must be a “new and useful 
process, machine, manufacture, or composition of matter, or any new and 
useful improvement thereof.”8  When enacting this statute, Congress 
intended it be interpreted broadly in order to cover “anything under the 
sun made by man.”9  While incredibly broad, the Court has recognized 
three main limitations: an inventor cannot patent the laws of nature, 
physical phenomena, or abstract ideas.10  “The concepts covered by these 
exceptions are ‘part of the storehouse of knowledge of all men . . . free to 
all men and reserved exclusively to none.’”11 
 
                                                          
7 35 U.S.C. § 101 (2006). 
 
8 Id. 
 
9 S. REP. NO. 82-1979, at 5 (1952). 
 
10 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
 
11 Bilski v. Kappos, 130 S. Ct. 3218, 3225 (2010) (quoting Funk Bros. Seed Co. v. Kalo 
Inoculant Co., 333 U.S. 127, 130 (1948)). 
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[3] Interpreting these exceptions, the Court in Diamond v. 
Chakrabarty was faced with the issue of whether a human-made, 
genetically engineered bacterium was patentable subject matter.12  The 
Court extended the prohibition on the patenting of the laws of nature to 
include the products of nature.13  To be patentable, the invention must be a 
product of human ingenuity; it must be “markedly different” from what 
exists in nature, “having a distinctive name, character, [and] use.”14  Thus, 
the Court concluded that by adding two oil-degrading plasmids 
Chakrabarty had created a new bacterium sufficiently different from that 
occurring in nature.15 
 
[4] In enunciating its “markedly different” standard, the Chakrabarty 
Court adopted the standard promulgated in Hartranft v. Wiegmann.16  The 
issue in Hartranft was whether a polished seashell was an article of 
manufacture.17  After harvesting, raw seashells were acid etched, ground 
to expose their interior layer, and then polished.18  The Court held that 
even though the shells had undergone changes, they still had the same 
“name, character, [and] use” as a shell picked up off the ground.19  Thus, 
                                                          
12 447 U.S. at 305. 
 
13 Id. at 313; see also H.R. REP. NO. 1129, at 7 (1930); S. REP. NO. 315, at 6 (1930). 
 
14 Diamond, 447 U.S. at 309-10 (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 
(1887)). 
 
15 Id. at 310. 
 
16 Id. at 309-10 (citing Hartranft, 121 U.S. at 609). 
 
17 Hartranft, 121 U.S. at 613. 
 
18 Id. at 611. 
 
19 Id. at 615. 
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the polished shells were not transformed into a different article of 
manufacture.20 
 
[5] The seashells in Hartranft are similar to the inoculant created in 
Funk Brothers Seed Co. v. Kalo Inoculant.21  In Funk Brothers, the Court 
sought to determine the validity of a patent for an inoculant containing 
several species of bacteria that were not mutually inhibiting.22  As the 
bacteria in the inoculant were identical to the bacteria as they existed in 
nature, the patent claimed the naturally occurring properties of the 
bacteria; the fact that when combined they do not inhibit the desirable 
properties of each other.23  Thus, the invention was held not patentable 
subject matter as it sought to claim the laws of nature.24  In the shadow of 
this precedent, the Federal Circuit took it upon themselves to decide the 
issue of whether human genes are patentable subject matter. 
 
III. THE MYRIAD DECISION 
 
[6] The controversy began in 2009 when Association for Molecular 
Pathology25 filed a declaratory judgment action against Myriad Genetics, 
                                                          
20 Id. 
 
21 See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948). 
 
22 Id. at 128. 
 
23 Id. at 131. 
 
24 Id. at 132. 
 
25 Association for Molecular Pathology was the first named party in the case.  Other 
plaintiffs include the American College of Medical Genetics, the American Society for 
Clinical Pathology, Breast Cancer Action, Boston Women’s Health Book Collective, 
eight doctors, and six women seeking breast cancer genetic testing.  Ass’n for Molecular 
Pathology v. U.S. Patent & Trademark Office (Myriad I), 702 F. Supp. 2d 181, 186-89 
(S.D.N.Y. 2010). 
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the University of Utah Research Foundation, and the U.S. Patent and 
Trademark Office (collectively “Myriad”) alleging fifteen claims, 
spanning seven patents, were invalid as unpatentable subject matter.26  
The patents at issue covered segments of “isolated DNA” and cDNA27 
from the BRCA1 and BRCA2 genes as well as methods for “analyzing” or 
“comparing” segments of isolated DNA to determine the presence of 
mutations.28  The BRCA1 and BRCA2 genes encode proteins integral in 
the repair of DNA breaks.29  Certain mutations in these genes have been 
observed to correlate to one’s susceptibility to breast and ovarian cancer.30 
 
[7] Recognizing the case’s significance, the district court concisely 
stated the issue: “[a]re isolated human genes . . . patentable?”31  The 
district court held human genes not patentable under § 101 because “DNA 
represents the physical embodiment of biological information” and thus 
falls under the law of nature exception to § 101.32  Myriad appealed to the 
Federal Circuit.33 
                                                          
26 Id. at 184 (challenging the validity of claims 1, 2, 5, 7, and 20 of U.S. Patent 5,747,282, 
claims 1, 6, and 7 of U.S. Patent 5,837,492, claim 1 of U.S. Patent 5,693,472, claim 1 of 
U.S. Patent 5,709,999, claim 1 of U.S. Patent 5,710,001, claim 1 of U.S. Patent 
5,753,441, and claims 1 and 2 of U.S. Patent 6,033,857). 
 
27 Isolated DNA is a nucleotide segment removed from the chromosome and separated 
from the extraneous cellular components. See infra Part V.D.  cDNA is a piece of 
artificially created DNA.  Id.  
 
28 Myriad II, 653 F.3d 1329, 1334-35 (Fed. Cir. 2011). 
 
29 Kiyotsugu Yoshida & Yoshio Miki, Role of BRCA1 and BRCA2 as regulators of DNA 
repair, transcription, and cell cycle in response to DNA damage, 95 CANCER SCI., 866, 
866-68 (2004). 
 
30 Myriad II, 653 F.3d at 1339; see also Wooster, supra note 1, at 2089. 
 
31 Myriad I, 702 F. Supp. 2d at 185. 
 
32 Id. 
 
33 Myriad II, 653 F.3d at 1333. 
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A. Federal Circuit: Judge Lourie’s Majority Opinion 
 
[8] In his opinion Judge Lourie characterizes three types of DNA: 
native DNA, isolated DNA, and cDNA.34  Native DNA is the single DNA 
molecule that composes each chromosome.35  Native DNA, as the name 
suggests, is the form of DNA exactly as found in nature.36  It contains both 
coding exon and non-coding intron regions of many genes.37  It is found 
covalently bonded to a complementary strand of DNA and wound around 
histones, proteins which “package” or condense the DNA into 
chromatin.38  Isolated DNA, on the other hand, is native DNA in which 
the histones have been removed and a sequence, containing an entire gene, 
has been cut out of the chromosomal structure.39  Finally, cDNA is a form 
of synthetic DNA, made by humans in a laboratory, containing only 
protein coding regions of DNA.40 
 
[9] Examining the patent eligibility of each of these types of DNA, 
Judge Lourie quickly decided the fates of genomic DNA and cDNA.  He 
correctly distinguished native DNA as existing in nature, thus preventing 
                                                                                                                                                
 
34 Id. at 1351-53. 
 
35 Id. at 1351. 
 
36 Id. 
 
37 Id. at 1339. 
 
38 Myriad II, 653 F.3d at 1338 fig.4. 
 
39 Id. at 1351-52.  Judge Lourie also incorrectly lumps isolated cDNA with isolated 
genomic DNA.  When considering isolated DNA, isolated cDNA should not be 
considered along with isolated genomic DNA.  Isolated cDNA is simply a shortened form 
of cDNA, and therefore should be analyzed as cDNA for the purposes of § 101. 
 
40 Id. at 1338-39. 
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patenting.41  As native DNA is devoid of any human innovation or 
modification, it is not patent-eligible subject matter under § 101.42  Judge 
Lourie also correctly found cDNA to be patentable subject matter.43  The 
creation of cDNA requires extensive human intervention and 
modification; it is quintessentially man-made.44  Therefore, Judge Lourie 
held it should be afforded patent protection under § 101.45 
 
[10] On the other hand, determining the patent eligibilty of isolated 
genomic DNA sequences required a more intricate analysis.  Examining 
isolated DNA, Judge Lourie compares it to its native counterpart from a 
chemical, as opposed to a biological, perspective.46  From a chemical 
perspective, the differences in DNA structure were compared, not the 
differences in information content characteristic of a biological 
perspective.47  Looking at the structure of the chromosomal DNA, Judge 
Lourie noted the chromosomes containing the BRCA1 and BRCA2 genes 
are approximately eighty million and one hundred fourteen million 
nucleotides in length, respectively.48  Yet, the actual genes are merely 
fragments of the astronomically large strands of DNA comprising each 
                                                          
41 See id. at 1351. 
 
42 See id. 
 
43 See Myriad II, 653 F.3d at 1350. 
 
44 See id. at 1338-39. 
 
45 Id. at 1350. 
 
46 Id. at 1351-53. 
 
47 Id. 
 
48 Myriad II, 653 F.3d at 1351-52. 
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chromosome.49  When the BRCA1 and BRCA2 genes are removed in the 
creation of isolated DNAs, each are approximately 7,000 and 11,000 base 
pairs in length, respectively.50  Judge Lourie states this extensive 
modification of the chemical structure of the genomic DNA makes 
isolated DNA’s structure markedly different from that of native DNA.51  
And for purposes of patentability, it is the change in physical structure of 
the molecule, not the information that is conveyed, that is the proper gauge 
for determining the differences from native form.52  Therefore, Judge 
Lourie concluded that the chemical bonds broken in the creation of 
isolated DNA are sufficient structural changes to warrant patent 
eligibility.53 
 
B. Federal Circuit: Judge Moore’s Concurrence-In-Part 
 
[11] Arriving at the same conclusion as the majority, Judge Moore 
applied a slightly different, more skeptical, analysis of the science.  As an 
initial matter, Judge Moore agreed that cDNA is patent eligible subject 
matter; it is made by man and is not found in nature.54  Next, she 
                                                          
49 BRCA2 is one of 720 genes composing the 115M bp of chromosome 13, and BRCA1 
is just one of the 1773 genes on the 81M bp chromosome 17.  NCBI Map Viewer, 
Chromosome 13, NAT’L CENTER FOR BIOTECHNOLOGY INFO., 
http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG=hum&MAPS=ideogr,est,loc&LI
NKS=ON&VERBOSE=ON&CHR=13 (last visited Mar. 19, 2012); NCBI Map Viewer, 
Chromosome 17, NAT’L CENTER FOR BIOTECHNOLOGY INFO., 
http://www.ncbi.nlm.nih.gov/mapview/maps.cgi?ORG=hum&MAPS=ideogr,est,loc&LI
NKS=ON&VERBOSE=ON&CHR=17 (last visited Mar. 19, 2012). 
 
50 Myriad II, 653 F.3d at 1351-52. 
 
51 Id. at 1352. 
 
52 Id. at 1353. 
 
53 Id. at 1352-53. 
 
54 Id. at 1364 (Moore, J., concurring). 
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examined the structural differences between isolated DNA and genomic 
DNA.  Agreeing with the majority, she found that the removal of a 
segment of DNA from the chromosome is a significant modification,55 but 
that modification only satisfies § 101 because the change imparts a whole 
new utility upon the isolated DNA molecule that is not present in the 
genomic DNA.56  Judge Moore qualifies this determination as being 
heavily influenced by the historical practice and examination guidelines of 
the U.S. Patent Office allowing isolated DNA claims.57  She notes that 
without this background, she might have found that an isolated gene is not 
patentable subject matter as it “serves the same ends devised by nature.”58 
 
C. Federal Circuit: Judge Bryson’s Concurrence-In-Part and 
Dissent-In-Part 
 
[12] Unlike the majority and concurring opinions, Judge Bryson 
concluded isolated DNA is not patentable subject matter as it is “not 
materially different from native genes.”59  Looking at the significance of 
the changes undergone in the creation of isolated DNA, he found the 
majority and concurrence placed too much emphasis on the breaking of a 
chemical bond.60  Chemical bonds are broken regularly in a vast myriad of 
processes: during the cutting and cleaning of diamonds or the isolation of 
                                                                                                                                                
 
55 Myriad II, 653 F.3d at 1364-65 (Moore, J., concurring). 
 
56 Id. at 1365. 
 
57 Id. at 1367 (citing Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093-94 (Jan. 5, 
2001)). 
 
58 Id. at 1366-67. 
  
59 Id. at 1373-75 (Bryson, J., dissenting). 
 
60 Myriad II, 653 F.3d at 1376. 
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the element lithium.61  Even in genetics, the chemical bonds holding the 
DNA backbone together are broken and reformed on a regular basis.62  
The routine nature of breaking chemical bonds therefore makes them an 
arbitrary method for determining patentability of DNA, especially when 
the method has been expressly rejected in the past.63 
 
[13] Rejecting the chemical approach of looking solely at structure, 
Judge Bryson likens the creation of isolated DNA to the snapping of a leaf 
from a tree.64  When a person snaps a leaf from a tree, she breaks chemical 
bonds that had previously attached it to the branch.  In doing so, she has 
imparted new characteristics and uses upon the leaf.  It no longer can be 
used to convert the sun’s energy into food, as nature would use it.  Rather, 
it can be used for decoration, consumption, or a myriad of other uses.  Yet, 
as Judge Bryson notes, even though the leaf was broken from the structure 
of the tree by man, and this breaking imparted a new utility not previously 
present, the leaf was created by nature, just as the tree was, and is 
therefore not patentable.65  Isolated DNA should be considered in the 
same manner.  Genomic DNA is created by nature.  While breaking off a 
small segment may impart some new utility, it does not change the fact 
that nature created that segment.  Therefore, Judge Bryson found DNA 
sequences isolated from genomic DNA unpatentable.66 
                                                          
61 Id. at 1375-77 (explaining that diamonds and lithium are not patentable, man-made 
inventions merely because they involve the breaking of chemical bonds). 
 
62 Topoisomerases, a type of enzyme, introduce nicks or double strand breaks into DNA 
to relieve supercoiling caused by DNA replication.  ROBERT F. WEAVER, MOLECULAR 
BIOLOGY 658 (4th ed. 2008). 
 
63 See Myriad II, 653 F.3d at 1376 (Bryson, J., dissenting). 
 
64 Id. at 1377. 
 
65 See id. 
 
66 Id. at 1375. 
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IV.  THE EFFECT OF MAYO V. PROMETHEUS LABORATORIES 
 
[14] In light of the recent decision Mayo Collaborative Services v. 
Prometheus Laboratories, Inc., the Federal Circuit was directed to 
reconsider its earlier decision that isolated human DNA is patentable.67  
While the Mayo decision related specifically to the patentability of 
processes claiming laws of nature, the Court’s reasoning provides 
significant insight on analyzing patentability decisions directly implicating 
the laws of nature and § 101.68  The Court’s rejection of insignificant or 
inconsequential steps following the direct application of a law of nature 
further bolsters the notion that a substantial human innovative contribution 
is required for patentability.69 
 
[15] Writing for the unanimous Court, Justice Breyer found 
Prometheus’ patents claimed unpatentable subject matter.70  The patents at 
issue claim methods for “optimizing [the] therapeutic efficacy” of treating 
certain autoimmune diseases.71  The claimed methods sought to recapture 
the correlation between the amount of a drug administered and the 
resulting physiological effect.72  The Court held this relationship alone 
                                                                                                                                                
 
67 Ass’n for Molecular Pathology v. Myriad Genetics, No. 11-725, 2012 WL 986819, at 
*1 (Mar. 26, 2012) (vacating the judgment and remanding to the Federal Circuit for 
reconsideration). 
 
68 See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 1294 
(2012). 
 
69 See id. at 1297. 
 
70 Id. at 1305. 
 
71 Id. at 1295 (quoting U.S. Patent No. 6,355,623 (filed Apr. 8, 1999)). 
 
72 Id. at 1296. 
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was a law of nature and therefore not patentable.73  In an attempt to 
circumvent a § 101 rejection, the claimed processes were drafted to 
include a transformative step to go beyond the law of nature.74  While 
these superfluous steps would likely avoid § 101 rejection under Bilski’s 
“machine or transformation test,” the Court found they “add[] nothing to 
the laws of nature that is not already present.”75  Thus, the Court held the 
addition of these “well-understood, routine, conventional” steps did not 
bestow patentability upon the law of nature.76 
 
[16] In announcing this opinion, the Court reiterated a basic patent 
principle: patents should promote scientific innovation.77  Thus, when 
examining patents involving the laws of nature, the scope of the claims 
should not be so broad as to “improperly t[ie] up the future use of the laws 
of nature.”78  To restrain further research into that law of nature would 
monopolize one of the “the basic tools of scientific and technological 
work”directly contradicting a fundamental goal of patent law.79  
  
[17] When the Federal Circuit reconsiders the patent eligibility of 
Myriad’s isolated DNA claims, it should be cognizant of the similarities 
                                                                                                                                                
 
73 Mayo Collaborative Servs., 132 S. Ct. at 1297. 
 
74 Id. 
 
75 Id. at 1298. 
 
76 Id. 
 
77 See id. at 1301; see also U.S. CONST. art. 1, § 8, cl. 8 (“To promote the Progress of 
Science and useful Arts, by securing for limited Times to Authors and Inventors the 
exclusive Right to their respective Writings and Discoveries.”). 
 
78 Mayo Collaborative Servs., 132 S. Ct. at 1301. 
 
79 Id. 
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between Prometheus’ and Myriad’s patents; each involves a law of nature 
followed by a superfluous step.  Just as the correlation between the 
quantity and effect of a drug is a law of nature, so too is a human gene.80  
Therefore, the added step of ‘isolating’ the whole gene from the 
chromosomal DNA should be analyzed like the “administering,” 
“wherein,” and “determining” steps of the Prometheus patents. 
 
[18] The step of ‘isolating’ DNA does not add sufficient novel subject 
matter to the inherent law of nature to enable patenting.  In order to 
transform a law of nature into patentable subject matter, the subsequent 
steps must be more than conventional, obvious, routine, or insignificant.81  
Like the “determining” and “wherein” steps of the Prometheus patent, the 
isolation of genomic DNA does nothing to change the law of nature 
embodied by the isolated gene.82  Rather, it is a universally known tool in 
molecular biology: exactly the type of “well understood, routine, 
conventional activity” already engaged in by the scientific community that 
was insufficient to transform patent eligibility in Prometheus.83  The 
claims directed towards isolated BRCA1 and BRCA2 genes do nothing 
more than attempt to monopolize the market in a law of nature embodied 
as the genes.  Therefore, the claims towards isolated DNA should be held 
not patentable subject matter. 
 
V.  ARE GENES PATENTABLE SUBJECT MATTER? 
 
                                                          
80 See id. at 1296. 
 
81 Id. at 1298. 
 
82 See infra Part V.A. 
 
83 Dennis Crouch, Mayo v. Prometheus: Natural Process + Known Elements = Normally 
No Patent, PATENTLYO (Mar. 20, 2012), 
http://www.patentlyo.com/patent/2012/03/mayo-v-prometheus-natural-process-known-
elements-normally-no-patent.html. 
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[18] Human genes, embodied as isolated DNA, are not patent-eligible 
subject matter.  As the Supreme Court recently vacated the Federal 
Circuit’s original Myriad ruling, they are again tasked with deciding 
whether isolated human DNA is patentable subject matter.84  The majority 
in the first Myriad decision incorrectly relied solely upon a chemical 
perspectiveconsidering changes to DNA’s structurewhen analyzing 
the differences between native and isolated DNA.85  When examining the 
patent eligibility of DNA, the Federal Circuit should examine both its 
information and structure.  The chemical perspective ignores the 
significance of the information content of DNA and, specifically, a gene.  
From a biological perspective, a piece of isolated DNA is identical to 
native DNA and, thus, fails the markedly different standard advanced by 
the court.86  When rehearing the issue on remand, the Federal Circuit 
should consider all aspects of DNA, both structure and information, when 
examining the eligibility of biological molecules. 
 
A. The Informational Significance of DNA 
 
[19] DNA is the blueprint of life.87  The information contained in DNA 
enables the creation of an entire human being.88  The DNA molecule itself 
                                                          
84 Ass’n for Molecular Pathology v. Myriad Genetics, No. 11-725, 2012 WL 986819, at 
*1 (Mar. 26, 2012). 
 
85 See Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 653 F.3d 1329, 
1351-53 (Fed. Cir. 2011). 
 
86 See, e.g., Myriad I, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010). 
 
87 Robert Aronson & Jacqueline McMurtie, The Use and Misuse of High-Tech Evidence 
by Prosecutors: Ethical and Evidentiary Issues, 76 FORDHAM L. REV. 1453, 1469 (2007). 
 
88 See WEAVER, supra note 62, at 32. 
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is not incredibly complex; it is composed of a series of nucleosides89 
joined in a chain by a phosphate group.90  Each nucleoside contains a 
deoxyribose sugar and one of four nitrogenous bases: adenine (“A”), 
thymine (“T”), cytosine (“C”), or guanine (“G”).91  Thus, the structure of 
DNA is composed of no more than repeating nucleotide segments of a 
nitrogenous base, the deoxyribose sugar, and the phosphate group 
arranged in a right-handed double helix.92  DNA molecules exist in the 
nucleus double stranded, or hydrogen bonded to a complementary piece of 
DNA, and wound around histone proteins in the chromatin.93  The 
histone’s function is to package the large volume of DNA so that it can fit 
within the nucleus.94  It simply binds the exterior of the DNA molecule 
and does not modify the DNA or its structure in any material way.95 
 
[20] While this structure is important to DNA’s function, it is the 
information contained in the nucleotide sequencethe order of the A, T, 
                                                          
89 Nucleosides and nucleotides are different entities.  A nucleotide contains a nucleoside 
as well as the phosphate group.  Id. at 16-17.  For the purposes of this comment, both are 
the functional equivalent. 
 
90 J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, 171 NATURE 737, 
737-38 (1953). 
 
91 Id. 
 
92 Id. 
 
93 WEAVER, supra note 62, at 23; Tony Kouzarides, Chromatin Modifications and Their 
Function, 128 CELL 693, 693 (2007). 
 
94 Kouzarides, supra note 93, at 693. 
 
95 WEAVER, supra note 62, at 40-41 (explaining how DNA fits into the grooves on the 
surface of the histone octamer and is only held in place through interactions with the 
histone tails). 
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C, and Gsthat makes DNA invaluable to an organism.96  When an 
organism activates a gene, it reads and copies the nucleotide sequence in 
the process of transcription and then uses the copied sequence to produce a 
protein during translation.97  During transcription, the cell’s machinery 
synthesizes a copy of the activated gene out of RNA.98  Then, the structure 
of the RNA is modified, including the removal of introns, to create 
mRNA.99  During translation, three base segments, known as codons, of 
the mRNA are ‘read’ such that a specific amino acid is incorporated into 
the nascent protein based on the sequence of the nucleotides within that 
codon.100  The protein is then incorporated into one of millions of 
processes of the organism.  Thus, by providing the blueprint for the 
creation of cellular proteins, the information contained in DNA is an 
important property that cannot be ignored. 
 
[21] It is important to note that transcription does not occur while the 
gene exists in its double stranded form as it would around histones.  In 
order for the gene to be activated for transcription, the histone proteins are 
stripped away by the cell’s machinery and the DNA strands are separated 
in what is known as the “transcription bubble.”101  Thus, when the actual 
informational content of the DNA is being accessed, the gene exists in a 
markedly similar state to that of isolated DNAsingle stranded and 
unbound to proteins. 
 
                                                          
96 Id. at 32 (explaining how the DNA sequence informs the creation of a protein). 
 
97 See id. at 40-46. 
 
98 WEAVER, supra note 62, at 40-41. 
 
99 Id. at 401. 
 
100 Id. at 44-46. 
 
101 Id. at 41, 369-71. 
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B. The Chemical Versus Biological Perspective 
 
[22] When examining the patent eligibility of human genes, there are 
two possible ways the subject matter can be examinedfrom a chemical 
or biological perspective.  The chemical perspective can be characterized 
by looking strictly at the structure of the molecules composing DNA.102  It 
looks solely at the molecular structure of DNA, the layout of the 
nucleotides and backbone, as well as any subsequent modification by 
humans.  Adopting this perspective, Judge Lourie, writing for the 
majority, concluded that simply breaking the DNA backbone and the 
unzipping of the double stranded structure amounted to a "markedly 
different" change from the genomic DNA.103  Examining the structure 
without regard to the information content it holds ignores a fundamental 
property of DNA. 
 
[23] On the other hand, the biological perspective examines the 
information content of the gene.  It looks not at the structure but at the 
information that structure reveals.  DNA is known as the 'blueprint of life' 
because it contains information that dictates the creation of an entire 
organism.104  While the structure does play a minor role in determining 
this information content, it is the genetic sequence, or order of the 
nucleotides within each gene, that contains the information.105  By simply 
                                                          
102 See, e.g., Myriad II, 653 F.3d 1329, 1353 (Fed. Cir. 2011). 
 
103 See id. at 1354.  Judge Lourie’s reliance on a chemical perspective could be explained 
by his background in chemistry; he holds a master’s degree in organic chemistry and a 
Ph.D. in chemistry.  Biography of Alan D. Lourie, Circuit Judge, UNITED STATES COURT 
OF APPEALS FOR THE FEDERAL CIRCUIT, http://www.cafc.uscourts.gov/judges/alan-d-
lourie-circuit-judge.html (last visited Jan. 16, 2012). 
 
104 See generally WEAVER, supra note 62, at 32 (characterizing the process by which 
DNA results in the creation of proteins). 
 
105 See id. 
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modifying the structure of the chromosome, i.e., excising a whole gene, no 
change is made to the information content of each gene.106  The 
unchanged genetic sequence and information content in the isolated DNA 
would fail the "markedly different" standard when compared to the 
sequence and information contained in the genomic DNA. 
 
[24] To exemplify this dichotomy between structure and information, 
consider an analogy from copyright law.  Consider a book.  A book is 
copyrightable with regard to the author’s exact portrayal of the 
information it contains.107  This is due in part to the fact that the societal 
value of the book is not in its structureits number of pages, type of 
cover, or method of binding.  Rather, the author’s original portrayal of the 
information in the book is what makes the book useful and deserving of a 
copyright.108  Thus, if a person copies a chapter of that book, she is an 
infringer.109  This infringer did not modify that chapter in any way.  She 
simply removed a piece of what already existed in the book and attempted 
to pass it off as her own.  While the chapter has a “markedly different” 
structure than the whole book, the portrayal of the information contained 
in the chapter is identical to what previously existed in the book.  The 
presence of that exact portrayal prevents the infringer from getting a new 
copyright even though the structure of the book is different because the 
significance of the book is not in its structure but in its content.110 
 
[25] The same result should be obtained in patent law, where genomic 
DNA is the book and isolated DNA is the chapter.  Native DNA, like a 
                                                          
106 See id. 
 
107 Feist Publ’ns, Inc. v. Rural Tel. Serv. Co., 499 U.S. 340, 348 (1991). 
 
108 Id. 
 
109 17 U.S.C. § 501(a) (2006). 
 
110 See id. 
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book composed of many chapters, is a unitary collection of many genes in 
a single strand of DNA.111  Likewise, isolated DNA is a chapter; the 
largest pieces of isolated DNA contain at most a single gene.112  As 
previously noted, the significance of DNA, both to the human body and 
for commercial exploitation, is mainly in its informational content, not its 
physical structure.113  Examining DNA’s patent eligibility solely based on 
its structural differences is the functional equivalent of granting copyrights 
on books based on the physical structure of the text.  When examined in 
this informational context, the information contained in the isolated DNA 
is not "markedly different" from the relevant portion of the genomic DNA, 
just as the information's portrayal in the chapter is not "markedly 
different" from the information's portrayal in the entire book.  Indeed, they 
are exactly the same.  Thus, just as one could not obtain a copyright for 
simply removing the chapter of a book, one cannot obtain a patent for 
simply isolating a specific sequence of DNA containing a gene. 
 
C. Isolated DNA is not Patentable Subject Matter 
 
[26] When determining whether a piece of DNA is patent eligible 
subject matter, the court should take a totality-of-the-circumstances 
approach, examining both the structure and information of the DNA.  
                                                          
111 See generally WEAVER, supra note 62, at 3. 
 
112 Myriad II, 653 F.3d 1329, 1338 (Fed. Cir. 2011).  A potential counterargument is that 
certain isolated DNAs are composed of substantially smaller portions of a gene, i.e., 
segments ranging from 10-100 nucleotides in length.  In this case, it can be argued that 
these smaller segments of DNA impart a markedly different utility upon the isolated 
DNA such that they should be afforded patent protection.  This is the functional 
equivalent of borrowing a string of three words from the text of a book.  It is virtually 
impossible to demonstrate that such a string is copyrightable; those three words likely are 
not a unique portrayal by an author.  In this way, they have a unique utility for each use 
just as smaller segments of isolated DNA have a different function than the entire gene. 
  
113 See supra, Part IV.A. 
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While both the District Court for the Southern District of New York and 
the Federal Circuit deemed these approaches mutually exclusive, the 
Supreme Court historically rejected the rigid application of a single test 
when deciding issues of patentability.114  In KSR International v. Teleflex 
Inc., the Court rejected the exclusive application of the “teaching, 
suggestion, or motivation test” when determining issues of obviousness 
under § 103.115  Similarly, in Bilski v. Kappos, the Supreme Court held 
when determining patentability of processes under § 101, the “machine-or-
transformation test” was not the sole test for patentability.116  While just a 
microcosm of the Court’s decisions, these cases demonstrate the Court’s 
proclivity for denying the application of narrow rules in patent law.  This 
sort of narrow application is precisely the analysis the lower courts 
performed when the district court looked solely at information and the 
Federal Circuit looked solely at structure.117  By considering both the 
structure and the information content, neither the immense biological 
significance of the nucleotide sequence nor the significance of structural 
modifications is discounted.   
 
[27] Applying the “markedly different” standard in this fashion reveals 
isolated genomic DNA is not sufficiently different from genomic DNA to 
be the subject of patent protection.  Examining both from biological and 
chemical perspectives reveal that the information contained in the isolated 
DNA, and the vast majority of its structure, is identical to that of genomic 
DNA.  While there are four covalent bonds cleaved in the creation of 
                                                          
114 See e.g., KSR Intern. Co. v. Teleflex Inc., 550 U.S. 398 (2007); Bilski v. Kappos, 130 
S. Ct. 3128 (2010). 
 
115 550 U.S. at 407, 415. 
 
116 Bilski, 130 S. Ct. at 3231. 
 
117 See Myriad I, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010); Myriad II, 653 F.3d 1329, 
1351-52 (Fed. Cir. 2011). 
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isolated DNA, this minor structural change is insufficient to outweigh the 
near identity of the two molecules to be considered “markedly different.” 
 
i. Information Content is Identical 
 
[28] Examining the information contained in the isolated DNA, it is not 
“markedly different” from the information contained in the genomic DNA.  
DNA contains information in its nucleotide sequence; the sequence 
dictates the creation of a specific protein.118  Thus, for the information 
content to be markedly different, the isolated DNA sequence must code 
for a protein sufficiently different from that found in nature. 
 
[29] Because of the nature of isolated genomic DNA, the protein 
resulting from transcription of the gene is identical to that resulting from 
transcription of native DNA.  Isolated DNA is produced by removing a 
specific genomic DNA sequence, usually an entire gene, from the rest of 
the cellular components.119  The piece of DNA ‘isolated’ was actually 
created by nature, with the exact same sequence, introns, and 
promoters.120  Therefore, with sequence identity to the native DNA, the 
isolated DNA contains the same information as found in the native gene.  
  
[30] This is exemplified by the ‘282 Patent where Claim 1 covers all 
isolated DNAs that encode for the BRCA1 protein.121  While the claim 
does not specify a sequence, the specification discloses the nucleotide 
                                                          
118 See supra Part V.A. 
119 U.S. Patent No. 5,747,282 col. 19 (filed Mar. 24, 1995).  Claim 1 claims a sequence of 
isolated DNA found in Seq. Id. No. 2.  Example 6 of the specification clarifies that the 
sequence contained in Seq. Id. No. 2 is the entire region containing the BRCA1 gene.  Id. 
at cols. 19, 153. 
 
120 Id. at col. 19. 
 
121 Id. at col. 153. 
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sequence of BRCA1 exactly as it is found in native DNA.122  The 
information contained the isolated DNA was not created by the ingenuity 
of man, rather it is the product of millions of years of evolution, devoid of 
any human input.  Therefore, the information contained in the isolated 
BRCA1 DNA is not “markedly different” from its genomic counterpart, 
and thus under Chakrabarty, the isolated DNA is not patent eligible 
subject matter. 
 
ii. Structure is Insignificantly Different 
 
[31] Aside from looking at the DNA’s information content, significant 
structural changes to the DNA could render it patentable subject matter.  
For instance, the synthesis of synthetic DNA, such as cDNA, has such a 
different structure from what is found in nature that it is rendered 
patentable.  Yet, the process of isolating genomic DNA in no way creates 
a “new . . . composition of matter” required by § 101.  In fact, the isolated 
DNA contains the exact same nucleotides, in the exact same sequence, as 
existed in the genomic DNA in vivo.123  The process of isolation is 
described as the “remov[al] from its naturally occurring 
environment.”124  Thus, modification of the sequence is not 
performed.  Isolation simply removes what had already existed in the cell. 
 
[32] This is exemplified by the claims of the ‘282 patent.  Claim 1 
covers an isolated DNA coding for the BRCA1 protein.125  As the claims 
of the patent are read in light of the specification, the claimed isolated 
DNA would be composed of a portion of the genomic DNA, removed 
                                                          
122 Id. at cols. 5-6. 
 
123 Id. at  col. 19 (defining “isolated” as simply the removal of naturally occurring DNA 
with no modification). 
 
124 U.S. Patent No. 5,747,282 col. 19 (filed Mar. 24, 1995). 
 
125 Id. at col. 153. 
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from the cellular proteins, coding for BRCA1.  The isolated piece of 
genomic DNA is disclosed to be 24,026 base pairs long, including the 
promoter and introns.126  The disclosed sequence even includes several 
regions where the sequence is unknown, designated by repeating ‘v’s in 
the patent.127  Accordingly, the structure of the claimed isolated DNA and 
the genomic DNA are identical.   
 
[33] While the main structure of the DNA is identical, there is one 
minor difference.  Four covalent bonds have been cleaved that held the 
segment-to-be-isolated into the DNA backbone.128  The cleaving of these 
four bonds, according to Judge Lourie, creates a “markedly different” 
molecule.129  But, examining the roots of the markedly different standard, 
this is the wrong conclusion.  The markedly different standard adopted by 
the Federal Circuit comes from the Supreme Court’s holdings in 
Chakrabarty and Hartranft.130  This standard originated in Hartranft to 
determine whether a seashell had undergone sufficient physical change to 
be converted from a natural object to a manufacture.131  The Court held 
that even the etching away of layers of shell via acid was not sufficient to 
fulfill the markedly different standard, because at its root, the shell was 
still a shell.132  In the case of isolated DNA, the breaking of four bonds, in 
                                                          
126 See, e.g., id. at fig. 10A-10H. 
 
127 Id. at col. 54. 
 
128 Myriad II, 653 F.3d 1329, 1351 (Fed. Cir. 2011). 
 
129 Id. at 1352. 
 
130 See generally Diamond v. Chakrabarty, 447 U.S. 303 (1980); Hartranft v. Wiegmann, 
121 U.S. 609 (1887). 
 
131 Hartranft, 121 U.S. at 614-15. 
 
132 Id. at 615. 
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light of the hundreds of thousands of bonds present in the entire molecule, 
is insignificant.  It is certainly a less extensive change than the acid 
removal of entire layers of shell in Hartranft.  Therefore, the breaking of 
these bonds cannot be considered to create a “markedly different” DNA 
molecule. 
 
D. cDNA is Patentable Subject Matter 
 
[34] The significant structural changes to the cDNA molecule outweigh 
the informational identity thus permitting its patenting under § 101.  
cDNA is a form of artificial DNA that is synthesized according to the 
mature mRNA transcript of a gene.133  The mature mRNA has undergone 
significant changes following transcription, most notably the excision of 
the introns, which can remove thousands of nucleotides.134  For example, 
the BRCA1 gene is shortened from 80,000 nucleotides in genomic form to 
just 7,000 nucleotides in the mRNA as a result of splicing.135  Scientists 
then take this mRNA, using reverse transcriptase, create a synthetic DNA 
molecule composed only of the coding exons that is found nowhere in 
nature.136  
  
[35] Under the totality of the circumstances approach, cDNA is 
patentable subject matter.  While cDNA codes for the exact same protein 
                                                          
133 WEAVER, supra note 62, at 64. 
 
134 Excision of the introns shortens the BRCA1 gene from 81,188 nucleotides in length to 
7,224 nucleotides.  See e.g., Homo sapiens breach cancer 1, early onset (BRCA1), 
transcript variant 1, mRNA, NIH NCBI GENBANK, 
 http://www.ncbi.nlm.nih.gov/nuccore/NM_007294.3 (last visited Jan. 16, 2012). 
 
135 Id. 
 
136 See SAMBROOK & RUSSELL, MOLECULAR CLONING: A LABORATORY MANUAL §§ 
11.1-11.19 (3d ed. 2001) (describing theory and current protocols for synthesizing 
cDNA). 
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as it is found in humans, the magnitude of the structural changes to the 
gene itself as well as its synthetic nature make it markedly different from 
anything found in a human.  As noted before, the significance in DNA’s 
information content requires significant structural modification to a native 
sequence to permit patenting.137  Unlike isolated DNA, which is derived 
from natural, genomic DNA, cDNA is synthesized by man in a test 
tube.138  It requires the specific isolation of the target mRNA intending to 
be replicated as well as the hybridization of a polythiamine primer to the 
polyadenine tail to foster the binding of the synthesis enzyme.139  The 
result is a molecule of DNA that exists with no introns, unlike the 
corresponding DNA sequence in the body.140  The combination of its 
synthetic nature and modified sequence amounts to sufficient changes to 
the cDNA’s structure to overcome the information identity and make it 
patent-eligible subject matter. 
 
VI.  CONCLUSION 
 
[36] Mired in the complexities of eukaryotic genetics, the 
straightforward question of whether human genes are patentable is easily 
lost.  The significance of each element of DNA has led each legal mind to 
consider this issue to conclude differently.  The district court and Federal 
Circuit’s dissent champion the supremacy of DNA’s information content.  
The majority and concurrence in the Federal Circuit supports the structural 
changes.  But, ignoring either the structure or the information undermines 
the importance of these fundamental properties.  Through a totality-of-the-
circumstances approach, both information and structure are weighed in 
order to determine whether the molecule as a whole is “markedly 
                                                          
137 See supra Part IV.A. 
 
138 See generally WEAVER, supra note 62, at 65. 
 
139 SAMBROOK & RUSSELL, supra note 136, § 11.12. 
 
140 Myriad II, 653 F.3d 1329, 1339 (Fed. Cir. 2011). 
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different” from genomic DNA, not just whether one property differs.  
Under this analysis, isolated genomic DNA is not patentable subject 
matter because of the structural changes undergone are relatively 
insignificant in light of the molecules identical information content, and 
cDNA is patentable subject matter because of the drastic, man-made 
manipulations of the molecule’s structure.  
